zyon-ayni

[zyon-ayni]

Zyon Ayni, Code Pharma CEO and Founder, won the Hua Hin Muay Thai Championship after defeating local champion Pet Pai Lin, 20 years younger than him.

[zyon-ayni]

CEO and Founder of Code Pharma, Zyon Ayni, said on IssueWire: “The entire team of Code Pharma is very excited today. We are a company of people playing an important role in the race to develop a cure for COVID-19. Our drug Codivir, was first discovered at the Hebrew University in Israel and it has a very good safety profile and very impressive antiviral activity”.

[zyon-ayni]

Zyon Ayni, CEO and founder of Code Pharma, told Yahoo Finance about the intention to launch an Initial Public Offering (IPO) and the limited fundraising round: “Today is a very exciting day for the Code Pharma team. We are well positioned to play a key role in the current race to develop a cure for COVID-19″.

[zyon-ayni]

Zyon Ayni, Founder and CEO of Code Pharma, tells Pressat about Codivir: “The company is preparing for a massive Phase II trial, which will be carried out on three continents and soon begin in South Africa, Spain and Brazil”.

[zyon-ayni]

#ציון עיני #Zyon Ayni

[zyon-ayni]

We are thrilled! We were able to announce that Codivir, our Covid-19 antiviral drug, was successful in its Phase 1 clinical trial. The is the first significant step in our important and exciting journey - with many more to come.

Antiviral drug Codivir, developed by Code Pharma BV, shows promising effect against COVID-19, wrote AP News. Codivir, a short synthetic 16 amino-acid peptide derived from the HIV-1 integrase, was initially discovered at the Hebrew University in Israel.

These results indicate that the drug can be used to treat COVID-19 patients suffering at different levels of severity. Due to its direct antiviral effect, Codivir may have a similar beneficial effect on other RNA viruses, such as influenza.

#Code Pharma #Zyon Ayni